Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Mabs
|
June 24, 2011
Emerging antibody combinations in oncology
Stephen J Demarest, Kandasamy Hariharan, Jianying Dong
Cancer Control : Journal of the Moffitt Cancer Center
|
April 20, 2002
Future of monoclonal antibodies in the treatment of hematologic malignancies
Mitchell E Reff, Kandasamy Hariharan, Gary Braslawsky
Blood
|
November 23, 2007
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines
Nuzhat I Pathan, Peter Chu, Kandasamy Hariharan, et al.
Molecular Cancer Therapeutics
|
January 24, 2012
Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs
Melisa A Martinez-Paniagua, Mario I Vega, Sara Huerta-Yepez, et al.
Vaccine
|
August 19, 2003
Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway, and dependency on CD80/CD86 costimulation
Nadeem A Sheikh, George S Attard, Nico van Rooijen, et al.
International Journal of Oncology
|
June 15, 2013
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine
Kandasamy Hariharan, Peter Chu, Tracey Murphy, et al.
Mabs
|
February 13, 2024
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma
Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, et al.
Cancer Research Communications
|
February 6, 2024
Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies
Henry Chan, Christina V Trout, David Mikolon, et al.
Molecular Cancer Therapeutics
|
August 19, 2010
Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response
Jianying Dong, Stephen J Demarest, Arlene Sereno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions
Mario I Vega, Sara Huerta-Yepez, Melisa Martinez-Paniagua, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Mabs
|
June 24, 2011
Emerging antibody combinations in oncology
Stephen J Demarest, Kandasamy Hariharan, Jianying Dong
Cancer Control : Journal of the Moffitt Cancer Center
|
April 20, 2002
Future of monoclonal antibodies in the treatment of hematologic malignancies
Mitchell E Reff, Kandasamy Hariharan, Gary Braslawsky
Blood
|
November 23, 2007
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines
Nuzhat I Pathan, Peter Chu, Kandasamy Hariharan, et al.
Molecular Cancer Therapeutics
|
January 24, 2012
Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs
Melisa A Martinez-Paniagua, Mario I Vega, Sara Huerta-Yepez, et al.
Vaccine
|
August 19, 2003
Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway, and dependency on CD80/CD86 costimulation
Nadeem A Sheikh, George S Attard, Nico van Rooijen, et al.
International Journal of Oncology
|
June 15, 2013
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine
Kandasamy Hariharan, Peter Chu, Tracey Murphy, et al.
Mabs
|
February 13, 2024
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma
Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, et al.
Cancer Research Communications
|
February 6, 2024
Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies
Henry Chan, Christina V Trout, David Mikolon, et al.
Molecular Cancer Therapeutics
|
August 19, 2010
Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response
Jianying Dong, Stephen J Demarest, Arlene Sereno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions
Mario I Vega, Sara Huerta-Yepez, Melisa Martinez-Paniagua, et al.
Page
of 2